{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T22:18:37Z","timestamp":1774304317596,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.urolonc.2024.03.013","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T20:05:58Z","timestamp":1714075558000},"page":"251-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of conduction hyperthermia in the treatment of non-muscle invasive bladder cancer: A systematic review"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-2060","authenticated-orcid":false,"given":"M. Teresa","family":"Melgarejo Segura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6167-0890","authenticated-orcid":false,"given":"Yaiza","family":"Y\u00e1\u00f1ez Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5282-814X","authenticated-orcid":false,"given":"Macarena","family":"Lozano Lorca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Morales Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9774-8485","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Arrabal Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-1811","authenticated-orcid":false,"given":"Miguel","family":"Arrabal Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.urolonc.2024.03.013_bib0001","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.013_bib0002","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0094-0143(03)00060-0","article-title":"Evaluation and follow-up strategies for superficial bladder cancer","volume":"30","author":"Donat","year":"2003","journal-title":"Urol Clin North Am"},{"issue":"1","key":"10.1016\/j.urolonc.2024.03.013_bib0003","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.03.013_bib0004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.03.013_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eururo.2004.01.019","article-title":"Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder","volume":"46","author":"van der Heijden","year":"2004","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.03.013_bib0006","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/02656736.2020.1780328","article-title":"Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study","volume":"37","author":"Tan","year":"2020","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"10.1016\/j.urolonc.2024.03.013_bib0007","first-page":"959","article-title":"A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment","volume":"153","author":"Colombo","year":"1995","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.03.013_bib0008","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/02656736.2014.900194","article-title":"A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer","volume":"30","author":"Sousa","year":"2014","journal-title":"Int J Hyperthermia"},{"issue":"8","key":"10.1016\/j.urolonc.2024.03.013_bib0009","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.7314\/APJCP.2015.16.8.3241","article-title":"Results of intravesical chemo-hyperthermia in high-risk non-muscle invasive bladder cancer","volume":"16","author":"Ekin","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"10.1016\/j.urolonc.2024.03.013_bib0010","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.3892\/or.2017.5570","article-title":"Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection","volume":"37","author":"Ba","year":"2017","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.urolonc.2024.03.013_bib0011","doi-asserted-by":"crossref","DOI":"10.1080\/02656736.2022.2129103","article-title":"Development and investigation of a novel device with gemcitabine for hyperthermic intravesical chemotherapy","volume":"40","author":"Jing","year":"2023","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.urolonc.2024.03.013_bib0012","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2024.03.013_bib0013","unstructured":"RoB 2_Cochrane Starter Pack_May2022_modified_080323.pdf [Internet]. [cited 2023 Oct 15]. Available from: https:\/\/methods.cochrane.org\/sites\/methods.cochrane.org\/files\/uploads\/inline-files\/RoB\/202_Cochrane\/20Starter\/20Pack_May2022_modified_080323.pdf"},{"key":"10.1016\/j.urolonc.2024.03.013_bib0014","unstructured":"Ottawa Hospital Research Institute [Internet]. [cited 2023 Oct 15]. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.013_bib0015","first-page":"496","article-title":"The impact of different adjuvant intravesical therapy methods on tumor biology in patients with high-risk non-muscle-invasive bladder cancer","volume":"74","author":"Kostyev","year":"2021","journal-title":"Cent European J Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2024.03.013_bib0016","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1007\/s00345-023-04332-z","article-title":"Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure","volume":"41","author":"Pignot","year":"2023","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.03.013_bib0017","doi-asserted-by":"crossref","first-page":"64","DOI":"10.26641\/2307-0404.2023.2.283254","article-title":"3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer","volume":"28","author":"Chystiakov","year":"2023","journal-title":"Medicni Perspektivi"},{"issue":"5","key":"10.1016\/j.urolonc.2024.03.013_bib0018","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3390\/cancers15051455","article-title":"Is CIS a contraindication to hyperthermic intravesical chemotherapy (HIVEC) after BCG-failure?","volume":"15","author":"Anastay","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2024.03.013_bib0019","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euo.2022.10.008","article-title":"Hyperthermic mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: results of the HIVEC-1 trial","volume":"6","author":"Angulo","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.03.013_bib0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2022.08.003","article-title":"Adjuvant Intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial","volume":"83","author":"Tan","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.03.013_bib0021","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1080\/02656736.2021.2002435","article-title":"Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy","volume":"38","author":"Doisy","year":"2021","journal-title":"Int J Hyperthermia"},{"issue":"2","key":"10.1016\/j.urolonc.2024.03.013_bib0022","doi-asserted-by":"crossref","first-page":"109.e1","DOI":"10.1016\/j.urolonc.2022.10.019","article-title":"Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer","volume":"41","author":"Melgarejo Segura","year":"2023","journal-title":"Urol Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2024.03.013_bib0023","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1007\/s00432-023-04688-0","article-title":"Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study","volume":"149","author":"Arrabal Polo","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.03.013_bib0024","unstructured":"Magalh\u00e3es JC, Sousa M, Basto R, Fraga T, Gomes I, Fernandes C, et al. Adjuvant hyperthermic intravesical chemotherapy in intermediate- and high-risk non-muscle invasive bladder cancer. Cureus. 15(9):e45672."},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.013_bib0025","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4103\/UA.UA_139_20","volume":"13","author":"Thyavihally","year":"2021","journal-title":"Urol Ann"},{"issue":"21","key":"10.1016\/j.urolonc.2024.03.013_bib0026","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.3390\/jcm10215105","article-title":"Long-term experience with hyperthermic chemotherapy (hivec) using mitomycin-C in patients with non-muscle invasive bladder cancer in Spain","volume":"10","author":"Plata","year":"2021","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.urolonc.2024.03.013_bib0027","doi-asserted-by":"crossref","first-page":"498.e13","DOI":"10.1016\/j.urolonc.2020.12.025","article-title":"Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage","volume":"39","author":"Grimberg","year":"2021","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.013_bib0028","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/02656736.2016.1142618","article-title":"Recirculant hyperthermic intravesical chemotherapy (HIVEC) in intermediate\u2013high-risk non-muscle-invasive bladder cancer","volume":"32","author":"Sousa","year":"2016","journal-title":"Int J Hyperthermia"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.013_bib0029","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4274\/uob.galenos.2019.1314","article-title":"Intravesical mitomycin-C with bladder wall hyperthermia in intermediate and high-risk non-muscle invasive bladder cancers: prospective clinical trial with a single-treatment arm","volume":"19","author":"Demirtas","year":"2020","journal-title":"Bulletin Urooncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.03.013_bib0030","doi-asserted-by":"crossref","first-page":"308","DOI":"10.20892\/j.issn.2095-3941.2020.0125","article-title":"A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer","volume":"18","author":"Ruan","year":"2021","journal-title":"Cancer Biol Med"},{"issue":"1","key":"10.1016\/j.urolonc.2024.03.013_bib0031","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1080\/02656736.2019.1646929","article-title":"Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate- and high-risk nonmuscle-invasive bladder cancer: a single-institution nonrandomized concurrent controlled trial","volume":"36","author":"Zhou","year":"2019","journal-title":"Int J Hyperthermia"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.013_bib0032","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.03.013_bib0033","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s11255-023-03849-x","article-title":"Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis","volume":"56","author":"Pazir","year":"2024","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.013_bib0034","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/03915603231189022","article-title":"The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance","volume":"90","author":"Akbulut","year":"2023","journal-title":"Urologia"},{"issue":"3","key":"10.1016\/j.urolonc.2024.03.013_bib0035","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/bco2.203","article-title":"Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients","volume":"4","author":"Conroy","year":"2023","journal-title":"BJUI Compass"},{"issue":"2","key":"10.1016\/j.urolonc.2024.03.013_bib0036","doi-asserted-by":"crossref","first-page":"62.e13","DOI":"10.1016\/j.urolonc.2021.07.019","article-title":"Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"Pijpers","year":"2022","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.03.013_bib0037","first-page":"287","article-title":"Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Gu\u00e9rin treatment failure","volume":"73","author":"Chiancone","year":"2020","journal-title":"Cent Eur J Urol"},{"issue":"5\u20136","key":"10.1016\/j.urolonc.2024.03.013_bib0038","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.5489\/cuaj.2708","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer","volume":"9","author":"Ekin","year":"2015","journal-title":"Can Urol Assoc J"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.013_bib0039","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","article-title":"Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients","volume":"4","author":"de Jong","year":"2018","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2024.03.013_bib0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4081\/aiua.2017.2.102","article-title":"Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer","volume":"89","author":"G\u00f6zen","year":"2017","journal-title":"Arch Ital Urol Androl"},{"issue":"2","key":"10.1016\/j.urolonc.2024.03.013_bib0041","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/ajco.13931","article-title":"Combination of hyperthermia and intravesical chemotherapy for the treatment of pT1 stage bladder cancer: A retrospectively clinical study","volume":"20","author":"Wang","year":"2024","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.03.013_bib0042","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00345-015-1595-3","article-title":"Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study","volume":"34","author":"Soria","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2024.03.013_bib0043","doi-asserted-by":"crossref","unstructured":"Wang S, Yu Z, Du P, Cao Y, Yang X, Ma J, et al. Combination of hyperthermia and intravesical chemotherapy for the treatment of pT1 stage bladder cancer: A retrospectively clinical study. Asia-Pacific J Clin Oncol [Internet]. [cited 2023 Nov 6];n\/a(n\/a). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/ajco.13931","DOI":"10.1111\/ajco.13931"},{"key":"10.1016\/j.urolonc.2024.03.013_bib0044","unstructured":"Demirtas. Intravesical mitomycin-C with bladder wall hyperthermia in intermediate and high-risk non-muscle invasive bladder cancers: prospective clinical trial with a single-treatment arm | Cochrane Library [Internet]. [cited 2022 Aug 24]. Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02243129\/full"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.013_bib0045","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.euf.2018.06.018","article-title":"Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Gu\u00e9rin","volume":"4","author":"Bandari","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.urolonc.2024.03.013_bib0046","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.03.013_bib0047","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1067\/j.cpradiol.2007.10.001","article-title":"Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences?","volume":"38","author":"Brace","year":"2009","journal-title":"Curr Probl Diagn Radiol"},{"issue":"10","key":"10.1016\/j.urolonc.2024.03.013_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276453","article-title":"The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumor in patients with nonmuscular invasive bladder cancer: A meta-analysis","volume":"17","author":"Zhou","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2024.03.013_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2021.775527","article-title":"Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis","volume":"8","author":"Zhao","year":"2021","journal-title":"Front Surg"},{"key":"10.1016\/j.urolonc.2024.03.013_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1164932","article-title":"Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette-Gu\u00e9rin instillation in non-muscle-invasive bladder cancer: a network meta-analysis","volume":"13","author":"Zeng","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2024.03.013_bib0051","article-title":"Efficacy and safety of HIVEC versus ETFT in non-muscle-invasive bladder cancer: A systematic review and meta-analysis","author":"Luo","year":"2023","journal-title":"Asian J Surg"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924003995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924003995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T02:13:13Z","timestamp":1718849593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924003995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1078143924003995"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.03.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of conduction hyperthermia in the treatment of non-muscle invasive bladder cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}